Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244525 | 0.85 | HPGD (0.43) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL5875667 | 0.81 | HSD17B10 (0.60) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL5875715 | 0.80 | KDM4E (0.42) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL5875862 | 0.79 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL29528876 | 0.79 | ALDH1A1 (0.43) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL2745279 | 0.79 | GABRA5 (0.46) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL17717276 | 0.79 | KMT2A (0.44) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL5240161 | 0.77 | NPC1 (0.46) | SMN1; SMN2TP53ALDH1A1KDM4EMAPT | |
| SCHEMBL11130654 | 0.77 | HSD17B10 (0.62) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL18649490 | 0.74 | HSD17B10 (0.50) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006504796-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | claimed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | disclosed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | APP, PARK7, IAPP | SMN1; SMN2 106/4885TP53 3350/4885MEN1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.